BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-121: Phase II data

Data from 99 patients with estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative breast cancer in the first cohort of an open-label, U.S. Phase II trial in 99 patients showed that weekly IV MM-121 plus paclitaxel followed by standard treatment with doxorubicin and cyclophosphamide until surgical resection led to a pCR rate of 10.8% vs. 3.3% for paclitaxel alone followed by...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >